PMN (ProMIS Neurosciences Inc. Common Shares (ON))
Insider Trading Activity
Every open-market purchase and sale reported by PMN officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-08-07 | Johanne Kaplan | Chief Development Officer | Buy | — | — |
| 2026-08-07 | Johanne Kaplan | Chief Development Officer | Buy | — | — |
| 2026-05-22 | Max A. Milbury | Principal Accounting Officer | A | — | — |
| 2026-05-22 | Neil K Warma | Chief Executive Officer | A | — | — |
| 2026-05-22 | Madge K. Shafmaster | Director | A | — | — |
| 2026-05-22 | Eugene Williams | Director | A | — | — |
| 2026-05-22 | Johanne Kaplan | Chief Development Officer | A | — | — |
| 2026-05-22 | WILLIAM W WYMAN | Director | A | — | — |
| 2026-05-22 | Josh Mandel-Brehm | Director | A | — | — |
| 2026-05-22 | Neil Cashman | Chief Scientific Officer | A | — | — |
| 2026-05-22 | Slanix Paul Alex | Director | A | — | — |
| 2026-04-23 | Patrick D. Kirwin | Director | Buy | — | — |
| 2026-03-06 | Eugene Williams | Director | Buy | — | — |
| 2026-03-04 | Eugene Williams | Director | Buy | — | — |
| 2026-02-23 | Johanne Kaplan | Chief Development Officer | Buy | — | — |
| 2026-02-05 | Max A. Milbury | — | A | — | — |
| 2026-02-05 | Johanne Kaplan | Chief Development Officer | A | — | — |
| 2026-02-05 | Patrick D. Kirwin | Director | A | — | — |
| 2026-02-05 | Ally Bridge Group (NY) LLC | 10%+ Owner | Buy | — | — |
| 2026-02-05 | Neil Cashman | Chief Scientific Officer | A | — | — |
| 2026-02-05 | Neil K Warma | Chief Executive Officer | A | — | — |
| 2025-10-24 | Ally Bridge Group (NY) LLC | 10%+ Owner | A | — | — |
| 2025-10-06 | Max A. Milbury | — | Buy | — | — |
| 2025-09-30 | Jeremy M. Sclar 2012 Irrevocable Family Trust | 10%+ Owner | X | — | — |
| 2025-09-24 | Johanne Kaplan | Chief Development Officer | A | — | — |
| 2025-09-24 | Max A. Milbury | — | A | — | — |
| 2025-09-24 | Neil Cashman | Chief Scientific Officer | A | — | — |
| 2025-09-24 | Neil K Warma | Chief Executive Officer | A | — | — |
| 2025-09-24 | LARRY DOUGLAS ALTSTIEL | Chief Medical Officer | A | — | — |
| 2025-09-08 | Jeremy M. Sclar | 10%+ Owner | X | — | — |
| 2025-08-14 | 19 Promis Title | — | X | — | — |
| 2025-08-14 | MICHAEL S GORDON | — | X | — | — |
| 2025-08-14 | MICHAEL S GORDON | — | J | — | — |
| 2025-07-29 | MICHAEL S GORDON | 10%+ Owner | X | — | — |
| 2025-07-29 | 19 Promis Title | 10%+ Owner | X | — | — |
| 2025-07-02 | MICHAEL S GORDON | 10%+ Owner | Sell | — | — |
| 2025-06-16 | Eugene Williams | Director | A | — | — |
| 2025-06-16 | Patrick D. Kirwin | Director | A | — | — |
| 2025-06-16 | Josh Mandel-Brehm | Director | A | — | — |
| 2025-06-16 | Madge K. Shafmaster | Director | A | — | — |
| 2025-06-16 | WILLIAM W WYMAN | Director | A | — | — |
| 2025-02-12 | Neil Cashman | Chief Scientific Officer | Buy | — | — |
| 2024-11-20 | LARRY DOUGLAS ALTSTIEL | Chief Medical Officer | A | — | — |
| 2024-11-20 | Neil Cashman | Chief Scientific Officer | A | — | — |
| 2024-11-20 | Max A. Milbury | Principal Accounting Officer | A | — | — |
| 2024-11-20 | Johanne Kaplan | Chief Development Officer | A | — | — |
| 2024-10-10 | Neil K Warma | Chief Executive Officer | A | — | — |
| 2024-10-07 | Eugene Williams | Director | A | — | — |
| 2024-10-07 | Josh Mandel-Brehm | Director | A | — | — |
| 2024-10-07 | Madge K. Shafmaster | Director | A | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | 10%+ Owner | 943,090 | — |
| — | 10%+ Owner | 123,111 | — |
| — | 10%+ Owner | 92,604 | — |
| — | 10%+ Owner | 87,817 | — |
| — | Director | 12,397 | — |
| — | Director | 9,788 | — |
| — | Principal Accounting Officer | 8,409 | — |
| — | Chief Development Officer | 6,221 | — |
| — | Chief Executive Officer | 6,183 | — |
| — | Chief Scientific Officer | 5,196 | — |
| — | Director | 2,733 | — |
| — | Chief Executive Officer | 2,208 | — |
| — | Chief Operating Officer | 106 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the PMN quote page; the site-wide leaderboard is on the insider transactions hub.